Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 4/20 | 0.41 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.38 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.38 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.38 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | GPR84 | Q9NQS5 | 3/20 | 0.35 |
| ▸ | CA1 | P00915 | 2/20 | 0.35 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | LCK | P06239 | 1/20 | 0.34 |
| ▸ | PPARD | Q03181 | 1/20 | 0.34 |
| ▸ | ZDHHC20 | Q5W0Z9 | 1/20 | 0.34 |
| ▸ | ZDHHC2 | Q9UIJ5 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21482210 | 0.98 | CA2 (0.43) | CA2GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL22198721 | 0.98 | CA2 (0.43) | CA2GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL21486156 | 0.98 | CA2 (0.43) | CA2GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL24462639 | 0.98 | CA2 (0.43) | CA2GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL24304106 | 0.97 | CA2 (0.46) | CA2GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL21482374 | 0.97 | CA2 (0.46) | CA2GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL23315005 | 0.95 | CA2 (0.41) | CA2GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL18909689 | 0.92 | CA2 (0.41) | CA2GRIK1GRIK2MAPK1GPR84 | |
| SCHEMBL19970160 | 0.92 | CA2 (0.39) | CA2GRIK1GRIK2SLC1A2SLC1A1 | |
| SCHEMBL21482325 | 0.83 | CA1 (0.44) | GPR84CA1FFAR1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200216423-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2020-07-09 | — | — | US | disclosed |
| US-10392368-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-08-27 | — | — | US | disclosed |
| US-20190040043-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | THERAVANCE BIOPHARMA R&D IP, LLC (US) | 2019-02-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190040043-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | JAK3, JAK1, JAK2 | CA2 2492/4885GRIK1 706/4885GRIK2 1071/4885 |
| US-10392368-B2 | Pyrazolo and triazolo bicyclic compounds as JAK kinase inhibitors | JAK3, JAK1, JAK2 | CA2 2492/4885GRIK1 706/4885GRIK2 1071/4885 |
| US-20200216423-A1 | PYRAZOLO AND TRIAZOLO BICYCLIC COMPOUNDS AS JAK KINASE INHIBITORS | JAK3, JAK1, JAK2 | CA2 2492/4885GRIK1 706/4885GRIK2 1071/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.